Search | Clinical Trials Finder

Conditions: Dysphagia, Lung Cancer, Pain, Esophagitis
Interventions: Manuka honey in liquid form, Manuka honey in lozenge form, Standard supportive care; Drug
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 59
States / cities: Mobile, Alabama • San Francisco, California • Stanford, California + 50 more

Conditions: KRAS Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions: Methotrexate, Pharmacokinetic Study, Regorafenib; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Lung Cancer
Interventions: EP-2101, incomplete Freund's adjuvant; Biological
Lead sponsor: Epimmune; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 9
States / cities: Ocoee, Florida • Albany, New York • Durham, North Carolina + 6 more

Conditions: Lung Cancer
Interventions: gemcitabine hydrochloride, oxaliplatin; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Miami, Florida • Tampa, Florida

Conditions: Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: dasatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: NSCLC
Interventions: BMS-986315, Nivolumab, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Glendale, California • Clermont, Florida • Orange City, Florida + 2 more

Conditions: Lung Cancer
Interventions: epothilone D; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: NSCLC (Non-small Cell Lung Carcinoma)
Interventions: Itacitinib, docetaxel; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 16
States / cities: Hot Springs, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 13 more

Conditions: Lung Cancer
Interventions: bevacizumab, carboplatin, erlotinib hydrochloride, paclitaxel, gene expression analysis, protein expression analysis, proteomic profiling, laboratory biomarker analysis; Drug · Genetic · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 7
States / cities: Gainesville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 2 more

Conditions: Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: docetaxel, bortezomib, laboratory biomarker analysis, immunoenzyme technique, immunohistochemistry staining method, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Duarte, California

Conditions: Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Interventions: APL-101 Oral Capsules; Drug
Lead sponsor: Apollomics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: cixutumumab, carboplatin, paclitaxel, cetuximab; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 249
States / cities: Stanford, California • Aurora, Colorado • Boulder, Colorado + 171 more

Conditions: Lung Cancer
Interventions: gemcitabine HCL, pemetrexed disodium; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Cervical Carcinoma, Metastatic Ovarian Carcinoma, Malignant Uterine Neoplasm, Vulvar Cancer, Invasive Breast Cancer, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Vulvar Carcinoma, Stage IV Cervical Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Vulvar Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Vulvar Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Vulvar Cancer AJCC v8, Vulva Squamous Cell Carcinoma
Interventions: Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer, Pancreatic Cancer
Interventions: LMB-9 immunotoxin; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer
Interventions: Ad5CMV-p53 gene, radiation therapy; Biological · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15; Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions: suramin, docetaxel, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: NSCLC (Non-small Cell Lung Carcinoma)
Interventions: Ruxolitinib, Placebo, Pemetrexed, Cisplatin; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 30
States / cities: Phoenix, Arizona • Fayetteville, Arkansas • Fresno, California + 27 more

Conditions: Lung Cancer, Metastatic Cancer
Interventions: cryosurgery, positron emission tomography; Procedure
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Recurrent Colon Cancer, Extensive Stage Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage III Non-small Cell Lung Cancer, Stage I Pancreatic Cancer, Stage II Non-small Cell Lung Cancer, Stage IVB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage IVA Pancreatic Cancer
Interventions: Detox-B adjuvant, ras peptide cancer vaccine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions: Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel; Biological · Drug
Lead sponsor: Genelux Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 15
States / cities: Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more

Conditions: Adult Solid Tumor
Interventions: CANscript; Diagnostic Test
Lead sponsor: Mitra RxDx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Timeline: 2017 – 2019
U.S. locations: 30
States / cities: Gilbert, Arizona • Aurora, Colorado • Norwich, Connecticut + 23 more

Conditions: Stomatitis
Interventions: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 39
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 35 more

Search by objective public record fields.

Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Epothilone D in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Platinum-Based Chemotherapy

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer

Pemetrexed Disodium and Gemcitabine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer

Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refractory Non-Small Cell Lung Cancer

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2

An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.